[1] 吴圣楣,陈惠金,朱建幸,等.新生儿医学[M].上海:上海科学技术出版社,2006:1001-1002. [2] 文伟,郭萌,张琦,等.新生儿先天性肾上腺皮质增生症筛查及不同胎龄、体重新生儿血17-羟孕酮变化[J].中国实用儿科杂志,2014,29(1):39-42. [3] 罗超,范歆,俸诗瀚,等.广西地区新生儿先天性肾上腺皮质增生症筛查切值的建立[J].中国优生与遗传杂志,2013,21(10):74-75. [4] Ryckman KK,Cook DE,Berberich SL,et al.Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns[J].J Pediatr Endocr Met,2012,25(3-4):301-305. [5] 中华人民共和国卫生部.新生儿疾病筛查规范[S].北京:中华人民共和国卫生部,2010. [6] 顾学范.新生儿疾病筛查[M].上海:上海科学技术出版文献出版社,2003:192. [7] Pitt JJ.Newborn screening[J].Clin Biochem Rev,2012,31(2):57-68. [8] Luxenberger K,Kasper D,Frohlich-Reiterer E,et al.Diagnosis and prevalence of congenital adrenal hyperplasia(CAH) in Austrian children screened or not screened for CAH[J].International Journal of Pediatric Endocrinology,2013(Supple 1):111. [9] Rabbani B,Mahdieh N,Ashtiani MTH,et al.Molecular diagnosis of congenital adrenal hyperplasia in Iran:focusing on CYP21A2 gene[J].Iran J Pediatr,2011,21(2):139-150. [10] 田丽萍,卜晓萍.济南地区新生儿先天性肾上腺皮质增生症的筛查分析[J].中国妇幼保健,2012,27(11):1666-1668. [11] Gonzalez EC,Carvajal F,Frometa A,et al.Newborn screening for congenital adrenal hyperplasia in Cuba:six years of experience[J].Clinica Chimica Acta.,2013,641:73-78. [12] 张馨尹,陈贻骥.17-羟孕酮在新生儿CAH筛查中的诊断意义[J].儿科药学杂志,2013,19(10):56-59. [13] 鲍培忠,叶军,韩连书,等.判别分析法在新生儿先天性肾上腺皮质功能增生症筛查中的应用[J].中华临床医师杂志:电子版,2013,7(17):7883-7886. |